Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma - PubMed (original) (raw)
. 2011 Nov;40(8):1276-82.
doi: 10.1097/MPA.0b013e318221bed8.
Hirofumi Kamachi, Hiroshi Nishihara, Shigenori Homma, Hiromi Kanno, Kenta Takahashi, Ayami Sasaki, Munenori Tahara, Kuniaki Okada, Shunji Muraoka, Toshiya Kamiyama, Yoshihiro Matsuno, Michitaka Ozaki, Satoru Todo
Affiliations
- PMID: 21775916
- DOI: 10.1097/MPA.0b013e318221bed8
Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma
Takahiro Einama et al. Pancreas. 2011 Nov.
Abstract
Objectives: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma.
Methods: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level expression, defined as expression by more than 50% of tumor cells and/or moderate to strong staining, or low-level expression otherwise.
Results: A high level of mesothelin was correlated with a higher histological grade (P = 0.049) and the level of blood vessel permeation (P = 0.0006), whereas a high level of CA125 expression was correlated with a higher recurrence rate (P = 0.015). The expression of mesothelin was strongly correlated with that of CA125 (P = 0.0041). Co-expression of mesothelin and CA125 were associated with an unfavorable patient outcome (P = 0.0062).
Conclusions: This is the first report showing that co-expression of mesothelin and CA125 were in pancreatic ductal adenocarcinoma, and such co-expression is associated with a poor prognosis. Our finding suggests that co-expression of these two factors plays a significant role in the acquisition of aggressive clinical behavior.
Similar articles
- High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome.
Einama T, Kagata Y, Tsuda H, Morita D, Ogata S, Ueda S, Takigawa T, Kawarabayashi N, Fukatsu K, Sugiura Y, Matsubara O, Hatsuse K. Einama T, et al. Pancreas. 2006 May;32(4):376-81. doi: 10.1097/01.mpa.0000220862.78248.c4. Pancreas. 2006. PMID: 16670630 - Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, Kosuge T, Kanai Y, Kitajima M, Hirohashi S. Nitori N, et al. Clin Cancer Res. 2005 Apr 1;11(7):2531-9. doi: 10.1158/1078-0432.CCR-04-0866. Clin Cancer Res. 2005. PMID: 15814630 - Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H. Liang JJ, et al. Clin Cancer Res. 2008 Nov 1;14(21):7043-9. doi: 10.1158/1078-0432.CCR-08-0381. Clin Cancer Res. 2008. PMID: 18981001 - Microenvironmental factors and extracellular matrix degradation in pancreatic cancer.
Binker MG, Binker-Cosen MJ, Binker-Cosen AA, Cosen-Binker LI. Binker MG, et al. JOP. 2014 Jul 28;15(4):280-5. doi: 10.6092/1590-8577/2638. JOP. 2014. PMID: 25076320 Review. - Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.
Winter JM, Yeo CJ, Brody JR. Winter JM, et al. J Surg Oncol. 2013 Jan;107(1):15-22. doi: 10.1002/jso.23192. Epub 2012 Jun 21. J Surg Oncol. 2013. PMID: 22729569 Review.
Cited by
- Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6.
Lee YE, Go GY, Koh EY, Yoon HN, Seo M, Hong SM, Jeong JH, Kim JC, Cho D, Kim TS, Kim SC, Jun E, Jang M. Lee YE, et al. J Immunother Cancer. 2023 Feb;11(2):e006130. doi: 10.1136/jitc-2022-006130. J Immunother Cancer. 2023. PMID: 36849201 Free PMC article. - Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization.
Ewa T, Panchwagh N, Tai CH, Avula LR, Joseph S, Rudloff MW, Malik N, Zhang X, Alewine C. Ewa T, et al. FASEB J. 2024 Dec 13;38(24):e70247. doi: 10.1096/fj.202400446R. FASEB J. 2024. PMID: 39673668 Free PMC article. - Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors.
Weidemann S, Gagelmann P, Gorbokon N, Lennartz M, Menz A, Luebke AM, Kluth M, Hube-Magg C, Blessin NC, Fraune C, Möller K, Bernreuther C, Lebok P, Clauditz TS, Jacobsen F, Izbicki JR, Jansen K, Sauter G, Uhlig R, Wilczak W, Steurer S, Minner S, Burandt E, Krech RH, Dum D, Krech T, Marx AH, Simon R. Weidemann S, et al. Biomedicines. 2021 Apr 7;9(4):397. doi: 10.3390/biomedicines9040397. Biomedicines. 2021. PMID: 33917081 Free PMC article. - Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.
Das S, Rachagani S, Torres-Gonzalez MP, Lakshmanan I, Majhi PD, Smith LM, Wagner KU, Batra SK. Das S, et al. Oncotarget. 2015 Mar 20;6(8):5772-87. doi: 10.18632/oncotarget.3308. Oncotarget. 2015. PMID: 25691062 Free PMC article. - Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.
Pandey V, Storz P. Pandey V, et al. Expert Rev Anticancer Ther. 2019 Jun;19(6):473-482. doi: 10.1080/14737140.2019.1622417. Epub 2019 May 31. Expert Rev Anticancer Ther. 2019. PMID: 31148495 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous